From Lecheng to Production: How Hainan Is Building a Medical Innovation Pipeline

Hainan is beginning to turn one of Lecheng’s most distinctive regulatory advantages into something broader: a route that can take selected overseas drugs and medical devices from early clinical use in China through registration and, in some cases, into production on the island.

The idea is no longer confined to a single project. At a late-June press conference, Hainan’s drug regulator said three products had already reached local production through the wider effort to link Lecheng use, real-world research, domestic registration and manufacturing. The regulator did not identify all three at product level, but one case, Trilaciclib, can be followed publicly through every stage from first use in Lecheng to production in Haikou.

A second major drug, ruxolitinib phosphate cream, has now completed the Lecheng and national-approval stages while its Hainan production base is being built. Medical devices are also being brought into the same framework.

What began as cooperation between Lecheng and Haikou is therefore starting to look more like a province-wide industrial strategy.

Trilaciclib showed that the route could work

Trilaciclib, marketed in China as Cosela, provides the clearest example.

The drug was first used in China through Lecheng’s special-access policy in June 2021 and entered Hainan’s real-world-data pilot two months later. Simcere says the Lecheng study provided supporting evidence during the Chinese registration process. The National Medical Products Administration (NMPA) granted the drug conditional approval in July 2022, which was converted to regular approval in October 2023.

In December 2023, the NMPA approved a supplemental application transferring the product to domestic manufacture by Hainan Simcere Pharmaceutical, with the production site in Haikou. The first locally produced batch, about 20,000 vials, came off the production line in Haikou National High-tech Industrial Development Zone on April 1, 2024. The production line was designed for annual capacity of up to 2 million vials.

That sequence demonstrates the complete route in practice: early access in Lecheng, real-world research, national approval and production in Haikou.

It also gave Hainan something that policy alone could not provide, a working precedent.

Ruxolitinib is moving through the same route

Ruxolitinib phosphate cream is moving along the same path.

Developed by Incyte, the product entered special-access clinical use in Lecheng in August 2023 and was later included in Hainan’s real-world-data programme. A January 2026 HKEX filing from China Medical System said a Chinese real-world study produced results consistent with the product’s overseas pivotal trials. The licensing agreement covers mainland China, Hong Kong, Macau, Taiwan and 11 Southeast Asian countries.

The NMPA approved the product in January 2026 for patients aged 12 and above with non-segmental vitiligo involving the face. A second indication, for mild-to-moderate atopic dermatitis, was approved on September 2.

The manufacturing stage is not yet complete.

In January, Dermavon said it was preparing the application for local production while its Haikou factory and production line were under construction. Hainan Daily subsequently reported that local production was expected in 2027. In August, CMS said the main structure of Dermavon’s Hainan R&D and manufacturing base was about to be topped out.

Ruxolitinib is on course to become another product to move from Lecheng use into Hainan manufacturing.

The strategy has widened from Haikou to Hainan

The policy behind this model predates 2026.

Hainan’s 2025 Government Work Report called for the province to advance the “Lecheng research and application + Haikou production” model in innovative drugs and medical devices.

The wording changed significantly in the 2026 report.

Under its advanced-manufacturing programme, the 2026 Government Work Report called for deepening the “Lecheng research/use + Hainan production” model, accelerating pharmaceutical and medical-device R&D results and promoting local production of introduced drugs and devices.

The change from “Haikou production” to “Hainan production” is small linguistically but important industrially. The model is no longer being framed only as cooperation between one medical zone and one manufacturing park. It is being positioned as part of Hainan’s wider manufacturing strategy.

That was followed on May 27 by a dedicated set of measures from the Hainan Medical Products Administration covering imported innovative and improved drugs. The final document was approved by the regulator and issued for implementation that day.

The measures explicitly connect Lecheng’s special-access and real-world-data systems with production in Hainan. They encourage multinational pharmaceutical companies conducting clinical research in Lecheng to plan production lines at the same time in Haikou National High-tech Industrial Development Zone and other key parks. For products whose registration is supported by qualifying Lecheng real-world data and which are intended for Hainan production, the regulator provides early intervention and guidance on production facilities and GMP requirements.

That begins to change the commercial proposition. Instead of Hainan trying to attract manufacturing only after a product has completed the Chinese approval process, the province wants the production decision considered while the product is still moving through Lecheng.

Medical devices are part of the same plan

Medical devices are following a similar route.

Hainan introduced dedicated high-end medical-device measures in October 2025 and amended and reissued them in September 2026. The September amendment changed two provisions, while retaining the core localisation framework established in 2025.

The current measures encourage international innovative devices to enter use through Lecheng and support devices first used there in locating manufacturing operations in Hainan. The regulator describes the intended chain as “research/use — conversion — production — distribution”. The measures also provide registration support, land-approval coordination, infrastructure assistance and guidance on relevant Free Trade Port zero-tariff and processing value-added policies.

One device has already advanced part of the way through that process.

A polyester-collagen bone-repair material introduced from Switzerland by Hainan SuSheng Biotechnology was first used in Lecheng in 2023 and received NMPA approval in February 2025. Hainan’s drug and medical-device review centre described it as the first medical-device product cultivated under the “Lecheng research/use + Haikou production” model. The same official notice said the company intended to work with the overseas licence holder to achieve local production in Haikou.

It has not yet reached the manufacturing stage completed by trilaciclib, but it expands the model beyond pharmaceuticals.

The pipeline behind the first projects is growing

The number of products reaching manufacturing is still small compared with the number entering through Lecheng, but the pool from which future localisation projects could emerge is becoming larger.

At the late-June press conference, Hainan said 27 drug and medical-device products had gained accelerated approval with support from real-world evidence generated through Lecheng, while three products had reached local production.

A separate July meeting of the Hainan Medical Products Administration reported that 48 drug and medical-device products had entered Lecheng’s real-world-research programme and 28 had been approved for market. The focus is now shifting to the practical work of scaling the model. The regulator said it would explore asset-light routes including contract R&D, segmented production and shared manufacturing to help more products establish operations in Hainan.

That points to the next stage of the model.

Lecheng already gives Hainan a recognised entry point for international medical products. Haikou has demonstrated that at least one of those products can move from early use into domestic manufacturing. The province is now broadening that relationship across Hainan and building policies around keeping more of the value created after registration on the island.

The next test will be how many products follow trilaciclib through the entire chain.

If ruxolitinib reaches local production as planned, more medical devices move beyond registration into manufacturing, and the regulator’s existing pipeline continues to produce localisation projects, Lecheng’s role could become considerably larger than early access alone.

It could become the front end of a medical-manufacturing pipeline for the Hainan Free Trade Port.

Related article: How Hainan Is Turning Aircraft Maintenance Into a Free Trade Port Industry

The Future of Aviation Business in Hainan Is Taking Shape in Haikou
The Future of Aviation Business in Hainan Is Taking Shape in Haikou
The future of aviation business in Hainan is beginning to take shape in Haikou. Foreign airline maintenance, engine overhaul, parts supply and aircraft dismantling are now operating around the airport, with a major bonded-zone expansion planned to support the next stage of growth …
www.tropicalhainan.com

Latest Forum Discussions

- Follow Us on WeChat -

spot_img

Related articles:

UK, Swedish, Thai and Malaysian acts booked for Chengmai music festival

Chengmai Lidao Music Festival III runs from 18 to 20 December 2026, with four international acts on the final day. See the line-up, ticket prices and entry rules ...

Why Alibaba’s cheaper AI could end up costing you more

Alibaba’s Qwen4-Max is cheaper per token, but independent tests found it cost over three times as much per task as GPT-6.2 Sol and took longer ...

Hainan Museum shows Titian and Ming-Qing painting until 18 April 2027

Works by Titian and Bellini from Glasgow Museums are on show at Hainan Museum until 18 April 2027, alongside a changing selection of Ming and Qing paintings and calligraphy ...

Richard Clayderman brings piano concert to Haikou on 6 December

Richard Clayderman brings his Forever Love piano concert to Haikou on 6 December 2026 at 19:30. Tickets range from 180 to 1,280 yuan ...

Get weekly email updates for new articles published!

Follow Us on WeChat

spot_img

Latest Articles ...

An arrivals duty-free shop opened on 13 November in Terminal 2 of Haikou Meilan airport. You can now shop duty-free before you clear customs ...
Five Danzhou companies joined Hainan's smart factory lists in 2026, which now name 18 companies at the advanced level against a 2027 target of 20 ...
Sanya Bay hosts seven jet ski sprints and an endurance race from 27 to 29 November 2026, followed by youth racing from 30 November to 1 December ...
Hainan's state-owned firms plan RMB 26.6 billion for 26 projects in seed breeding, marine industries, space, green industries and data through 2030 ...
spot_img

How to Claim Your Housing Provident Fund Before You Leave China

Foreign employees in China may have a Housing Provident Fund account they have never checked. The balance, employer contributions included, can be withdrawn in full when you leave. Here is how to claim it before you go …

Leaving China? Here’s the Pension Money Most Expats Never Claim

You contributed 8% of your salary to a Chinese pension account every month. Many expats leave without claiming it. Here is a breakdown of what you are owed and the window you cannot afford to miss ...

Why Your Name Doesn’t Match Across Chinese Systems, and What to Do About It

Your name exists in five different systems in China. Zero automated checks and they don't talk to each other. Here's what happens when they disagree ...

Why Foreigners Lose Access to Their Chinese Bank Accounts

Frozen accounts, blocked cards, restricted access. Most expats in China don't think about their bank account until they can't access it …
spot_img

Looking for an international pre-school in Haikou?

Flora's International Preschool has three preschools in the Haikou area. Our schools follow a European curriculum

Continue Reading ...

UK, Swedish, Thai and Malaysian acts booked for Chengmai music festival

Chengmai Lidao Music Festival III runs from 18 to 20 December 2026, with four international acts on the final day. See the line-up, ticket prices and entry rules ...

Why Alibaba’s cheaper AI could end up costing you more

Alibaba’s Qwen4-Max is cheaper per token, but independent tests found it cost over three times as much per task as GPT-6.2 Sol and took longer ...

Hainan Museum shows Titian and Ming-Qing painting until 18 April 2027

Works by Titian and Bellini from Glasgow Museums are on show at Hainan Museum until 18 April 2027, alongside a changing selection of Ming and Qing paintings and calligraphy ...

Get weekly email updates for new articles published!

Never miss another important notice or event. Be informed of what you need to know, when you need to know it.